We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Dose-range Finding Efficacy and Safety Study for QBW251 in COPD Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04072887
Recruitment Status : Completed
First Posted : August 28, 2019
Last Update Posted : July 29, 2022
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

Brief Summary:
This clinical study was designed to support the dose selection for future studies by evaluating efficacy and safety of different QBW251 doses in Chronic obstructive pulmonary disease (COPD) patients with chronic bronchitis and a history of exacerbations, compared to placebo, when added to a triple inhaled therapy of LABA, LAMA and ICS.

Condition or disease Intervention/treatment Phase
Pulmonary Disease, Chronic Obstructive Drug: QBW251 Drug: Placebo Drug: COPD maintenance background therapy Phase 2

Detailed Description:

This study used a 6 treatment arm, parallel-group, randomized, double-blind study design. 974 male and female COPD patients were randomized into the trial. The study consisted of four distinct study periods:

  • Screening (Weeks -3 to -2): Participants underwent a screening period of 1 week where were assessed for eligibility and tapered off disallowed medications.
  • Run-in (Days -14 to 1): Subsequently, participants entered the run-in period of up to 2 weeks to establish baseline values for symptom assessments, to standardize the COPD background therapy (triple combination LABA/LAMA/ICS), and to complete eligibility assessments.
  • Treatment (Day 1 to Week 24): Eligible participants moved into the Day 1 visit where they were stratified according to their smoking status (current or ex-smoker) and severity of airflow limitation (FEV1 ≥ 30% to < 50% and ≥ 50% to < 80%) and then randomized into 1 of 6 treatment arms with a randomization ratio of 2:2:1:1:1:2 (450 mg b.i.d., 300 mg b.i.d., 150 mg b.i.d., 75 mg b.i.d., 25 mg b.i.d., placebo). The treatment period consisted of 24 weeks, during which the participant returned to the site for regular visits (Day 1 - Week 24).
  • Follow-up (Weeks 25-28): Upon completion of the treatment period, participants were followed up for safety assessments for 30 days.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 974 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A 24-week Multi-center, Double-blind, Placebo Controlled Dose-range Finding Study to Investigate the Efficacy and Safety of Oral QBW251 in COPD Patients on Triple Inhaled Therapy (LABA / LAMA / ICS)
Actual Study Start Date : September 12, 2019
Actual Primary Completion Date : October 8, 2021
Actual Study Completion Date : February 1, 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: COPD

Arm Intervention/treatment
Experimental: QBW251 450 mg
QBW251 was orally administered 450 mg b.i.d for 24 weeks
Drug: QBW251
QBW251 oral capsules (450, 300, 150, 75 and 25 mg) of identical appearance to ensure blinding administered twice a day (b.i.d) for 24 weeks

Drug: COPD maintenance background therapy
Combination of fluticasone furoate, vilanterol and umeclidinium

Experimental: QBW251 300 mg
QBW251 was orally administered 300 mg b.i.d for 24 weeks
Drug: QBW251
QBW251 oral capsules (450, 300, 150, 75 and 25 mg) of identical appearance to ensure blinding administered twice a day (b.i.d) for 24 weeks

Drug: COPD maintenance background therapy
Combination of fluticasone furoate, vilanterol and umeclidinium

Experimental: QBW251 150 mg
QBW251 was orally administered 150 mg b.i.d for 24 weeks
Drug: QBW251
QBW251 oral capsules (450, 300, 150, 75 and 25 mg) of identical appearance to ensure blinding administered twice a day (b.i.d) for 24 weeks

Drug: COPD maintenance background therapy
Combination of fluticasone furoate, vilanterol and umeclidinium

Experimental: QBW251 75 mg
QBW251 was orally administered 75 mg b.i.d for 24 weeks
Drug: QBW251
QBW251 oral capsules (450, 300, 150, 75 and 25 mg) of identical appearance to ensure blinding administered twice a day (b.i.d) for 24 weeks

Drug: COPD maintenance background therapy
Combination of fluticasone furoate, vilanterol and umeclidinium

Experimental: QBW251 25 mg
QBW251 was orally administered 25 mg b.i.d for 24 weeks
Drug: QBW251
QBW251 oral capsules (450, 300, 150, 75 and 25 mg) of identical appearance to ensure blinding administered twice a day (b.i.d) for 24 weeks

Drug: COPD maintenance background therapy
Combination of fluticasone furoate, vilanterol and umeclidinium

Placebo Comparator: Placebo
Placebo was orally administered b.i.d for 24 weeks
Drug: Placebo
Placebo oral capsules administered twice a day for 24 weeks

Drug: COPD maintenance background therapy
Combination of fluticasone furoate, vilanterol and umeclidinium




Primary Outcome Measures :
  1. Change From Baseline in Forced Expiratory Volume in One Second (FEV1) at week 12 [ Time Frame: Baseline and Week 12 ]

    The primary efficacy analysis assessed the effect of QBW251 on the absolute change from baseline in trough FEV1 in liters on Week 12. Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Baseline measurement was defined as the baseline visit pre-bronchodilator spirometry assessment. A positive trend for change from baseline in FEV1 across the dose range is considered a favorable outcome.

    Change from baseline in the FEV1 mean scores were analyzed using a Mixed Model for Repeated Measures (MMRM): treatment + baseline score + smoking status at screening + run-in FEV1 + airflow limitation severity + region + time interval + treatment*time interval interaction + baseline score*time interval interaction.



Secondary Outcome Measures :
  1. Change From Baseline in Forced Expiratory Volume in One Second (FEV1) [ Time Frame: Baseline, weeks 4, 8, 16, 20 and 24 ]

    The primary efficacy analysis assessed the effect of QBW251 on the absolute change from baseline in trough FEV1 in liters compared to placebo on Weeks 4, 8, 16, 20 and 24. Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Baseline measurement was defined as the baseline visit pre-bronchodilator spirometry assessment. A positive trend for change from baseline in FEV1 across the dose range is considered a favorable outcome.

    Change from baseline in the FEV1 mean scores were analyzed using a Mixed Model for Repeated Measures (MMRM): treatment + baseline score + smoking status at screening + run-in FEV1 + airflow limitation severity + region + time interval + treatment*time interval interaction + baseline score*time interval interaction.


  2. Change from baseline in Evaluating Respiratory Symptoms (E-RS); Total score [ Time Frame: Baseline, weeks 12 and 24 ]

    The E-RS assesses overall daily respiratory COPD symptoms (Total score) and it is derived as the sum of 11 severity items; a higher scores indicate more severe symptoms.

    Change from baseline in the E-RS Total weekly mean scores were analyzed using a Mixed Model for Repeated Measures (MMRM): treatment + baseline score + smoking status at screening + run-in E-RS + airflow limitation severity + region + time interval + treatment*time interval interaction + baseline score*time interval interaction.

    The mean baseline E-RS Total score was the average of the corresponding daily scores from the run-in period. Lower scores in the change from baseline correspond to lower symptom severity.


  3. Change from baseline in Evaluating Respiratory Symptoms (E-RS); Cough and Sputum score [ Time Frame: Baseline, weeks 12 and 24 ]

    The E-RS assesses both overall daily respiratory COPD symptoms (Total score) and specific respiratory symptoms using 3 subscales (Breathlessness, Cough & Sputum, and Chest Symptoms). The E-RS comprises 11 severity items and higher scores indicate more severe symptoms. The Cough and Sputum subscale score was derived as the sum of items 2 - 4.

    Change from baseline in the E-RS Cough and Sputum weekly mean scores were analyzed using a Mixed Model for Repeated Measures (MMRM): treatment + baseline score + smoking status at screening + run-in E-RS + airflow limitation severity + region + time interval + treatment*time interval interaction + baseline score*time interval interaction.

    The mean baseline E-RS Cough & Sputum subscale score was the average of the corresponding daily scores from the run-in period. Lower scores in the change from baseline correspond to lower symptom severity.


  4. Number of Participants with a "Better" change in the Patient Global Impression of Severity (PGI-S) from baseline [ Time Frame: Baseline, weeks 12 and 24 ]
    The PGI-S questionnaire is a patient-reported outcomes score that rates the severity of the respiratory symptoms and of cough and mucus. The change in severity scores (Better, No change and Worse) from baseline were reported at weeks 12 and 24. Thus, the number of participants with a Better change in the severity score are reported in the table below.

  5. Change from baseline in the Cough and Sputum Assessment Questionnaire (CASA-Q) [ Time Frame: Baseline, weeks 12 and 24 ]

    The CASA-Q is a validated questionnaire instrument used to measure cough and sputum production, and their impact in patients COPD and/or chronic bronchitis. It contains a total of 20 items on a 5-step scale distributed in 4 domains: Cough symptoms, Cough impact, Sputum symptoms and Sputum impact. All items are rescored from 1-5 to 0-4 and then reverse scored such that better responses have higher scores. The four domains are ranged from 0-100 where higher scores associated with fewer symptoms/less impact due to cough or sputum. Within each domain, items are summed and rescaled: CASA-Q domain scores= (sum of rescored items) / (range of rescored items) ×100

    Change from baseline in the CASA-Q cough and symptoms scores were analyzed using a Mixed Model for Repeated Measures (MMRM): treatment + baseline score + smoking status at screening + run-in E-RS + airflow limitation severity + region + time interval + treatment*time interval interaction + baseline score*time interval interaction.


  6. Change from baseline in St. George's Respiratory Questionnaire (SGRQ) [ Time Frame: Baseline, weeks 12 and 24 ]

    SGRQ measures health impairment and contains 50 items divided into three components: Symptoms, Activity and Impacts. A score was calculated for each component and a "Total" score was also calculated. In each case the lowest possible value is zero and the highest 100. Higher values correspond to greater impairment of quality of life.

    Change from baseline in the SGRQ scores were analyzed using a Mixed Model for Repeated Measures (MMRM): treatment + baseline score + smoking status at screening + baseline SGRQ score + airflow limitation severity + region + time interval + treatment*time interval interaction + baseline score*time interval interaction.


  7. Minimum plasma concentration (Cmin) for QBW251 [ Time Frame: Days 15, 29, 57, 85, 113, 141 and 169 ]
    Venous whole blood samples were collected for pharmacokinetics characterization. Cmin was calculated from plasma concentration data using non-compartmental methods and summarized using descriptive statistics. Cmin was measured pre dose at all visits. All concentration below the lower limit of quantification (LLOQ) was treated as zero.

  8. Maximum plasma concentration (Cmax) for QBW251 [ Time Frame: Days 1, 15 and 169 ]
    Venous whole blood samples were collected for pharmacokinetics characterization. Cmax was calculated from plasma concentration data using non-compartmental methods and summarized using descriptive statistics. Cmax was estimated using the 3hr concentration for participants not in the Serial PK set. For participants in the Serial PK set, the calculated Cmax is presented only for Day 1 and Day 15. All concentration below the lower limit of quantification (LLOQ) was treated as zero.

  9. Maximum plasma concentration (Cmax) for QBW251 in Serial PK set [ Time Frame: Days 1 and 15 ]
    Venous whole blood samples were collected for pharmacokinetics characterization. Cmax was calculated from plasma concentration data using non-compartmental methods and summarized using descriptive statistics. All concentration below the lower limit of quantification (LLOQ) was treated as zero.

  10. Area under de curve from time 0 to 24 hours (AUC0-24h) of QBW251 in Serial PK set [ Time Frame: Days 1 and 15 ]
    Venous whole blood samples were collected for pharmacokinetics characterization. AUC0-24h was calculated from plasma concentration-time data using non-compartmental methods and summarized using descriptive statistics. AUC0-24h was estimated as 2 x AUC0-12h. All concentration below the lower limit of quantification (LLOQ) was treated as zero.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   40 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male and female COPD patients aged ≥40 years, who have signed an Informed Consent Form prior to initiation of any study-related procedure.
  • Current or ex-smokers who have a smoking history of at least 10 pack years.
  • Patients who have been treated with a triple combination of LABA/LAMA/ICS for the last 3 months prior to screening.
  • Patients featuring chronic bronchitis

Exclusion Criteria:

  • Patients who have had a COPD exacerbation that required treatment with antibiotics and/or oral corticosteroids and/or hospitalization, or a respiratory tract infection in the 4 weeks prior to screening, or between screening and randomization.
  • Patients with any documented history of asthma, or with an onset of chronic respiratory symptoms, including a COPD diagnosis, prior to age 40 years.
  • Patients with a body mass index (BMI) of more than 40 kg/m2.
  • Use of other investigational drugs (approved or unapproved) within 30 days or 5 half-lives prior to screening, or until the expected pharmacodynamic effect has returned to baseline (e.g., biologics), whichever is longer; or longer if required by local regulations.
  • Pregnant or nursing (lactating) women, and women of childbearing potential not willing to use acceptable effective methods of contraception during study participation.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04072887


Locations
Show Show 148 study locations
Sponsors and Collaborators
Novartis Pharmaceuticals
Layout table for additonal information
Responsible Party: Novartis Pharmaceuticals
ClinicalTrials.gov Identifier: NCT04072887    
Other Study ID Numbers: CQBW251B2201
2018-003197-28 ( EudraCT Number )
First Posted: August 28, 2019    Key Record Dates
Last Update Posted: July 29, 2022
Last Verified: July 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Novartis ( Novartis Pharmaceuticals ):
COPD
Additional relevant MeSH terms:
Layout table for MeSH terms
Pulmonary Disease, Chronic Obstructive
Lung Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive